PriceTargets.com logo

Neoleukin Therapeutics - NLTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $30.00
  • Forecasted Upside: -0.76%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$30.23 As of 04/24/2024 01:00 AM ET
▼ -0.94 (-3.02%)

This chart shows the closing price for NLTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Neoleukin Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NLTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NLTX

Analyst Price Target is $30.00
▼ -0.76% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Neoleukin Therapeutics in the last 3 months. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. The average price target represents a -0.76% upside from the last price of $30.23.

This chart shows the closing price for NLTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Neoleukin Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2023MizuhoLower Target$40.00 ➝ $30.00Low
1/3/2023GuggenheimDowngradeBuy ➝ NeutralLow
11/16/2022HC WainwrightDowngradeBuy ➝ NeutralLow
11/15/2022Canaccord Genuity GroupDowngradeBuy ➝ HoldLow
11/15/2022Canaccord Genuity GroupReiterated RatingBuy ➝ HoldLow
11/15/2022MizuhoDowngradeBuy ➝ Neutral$420.00 ➝ $40.00Low
11/15/2022GuggenheimDowngradeBuy ➝ NeutralLow
11/15/2022Stifel NicolausDowngradeBuy ➝ HoldLow
9/12/2022Bank of AmericaDowngradeBuy ➝ UnderperformLow
9/12/2022HC WainwrightLower TargetBuy$440.00 ➝ $120.00Low
7/6/2022Canaccord Genuity GroupReiterated RatingBuy$200.00N/A
5/27/2022Piper SandlerLower Target$500.00 ➝ $120.00Low
3/2/2022Piper SandlerLower TargetOverweight$600.00 ➝ $500.00High
1/11/2022HC WainwrightReiterated RatingBuy$440.00High
8/9/2021HC WainwrightReiterated RatingBuy$440.00High
4/28/2021HC WainwrightReiterated RatingBuyMedium
4/11/2021MizuhoReiterated RatingBuy$420.00Medium
1/5/2021Stifel NicolausInitiated CoverageBuy$360.00N/A
9/22/2020Robert W. BairdInitiated CoverageOutperform$500.00High
8/12/2020MizuhoReiterated RatingBuy$420.00High
8/12/2020Piper SandlerBoost TargetOverweight$560.00 ➝ $600.00High
6/24/2020Piper SandlerBoost Target$400.00 ➝ $560.00High
6/23/2020MizuhoReiterated RatingBuy$420.00High
6/17/2020MizuhoInitiated CoverageBuy$420.00High
5/18/2020HC WainwrightReiterated RatingBuy$440.00High
5/7/2020HC WainwrightReiterated RatingBuy$440.00High
4/13/2020HC WainwrightInitiated CoverageBuy$440.00High
3/16/2020Bank of AmericaInitiated CoverageBuy$360.00High
2/18/2020GuggenheimInitiated CoverageBuy$400.00Medium
1/10/2020Piper SandlerInitiated CoverageOverweight$400.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Neoleukin Therapeutics logo
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $30.23
Low: $29.51
High: $30.96

50 Day Range

MA: $37.24
Low: $13.96
High: $50.90

52 Week Range

Now: $30.23
Low: $2.03
High: $14.36

Volume

52,572 shs

Average Volume

50,104 shs

Market Capitalization

$284.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of Neoleukin Therapeutics?

The following Wall Street analysts have issued reports on Neoleukin Therapeutics in the last year: Mizuho.
View the latest analyst ratings for NLTX.

What is the current price target for Neoleukin Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Neoleukin Therapeutics in the last year. Their average twelve-month price target is $30.00, suggesting a possible downside of 0.8%. Mizuho has the highest price target set, predicting NLTX will reach $30.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $30.00 for Neoleukin Therapeutics in the next year.
View the latest price targets for NLTX.

What is the current consensus analyst rating for Neoleukin Therapeutics?

Neoleukin Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NLTX.

What other companies compete with Neoleukin Therapeutics?

Other companies that are similar to Neoleukin Therapeutics include Kamada, Erasca, Verrica Pharmaceuticals, Contineum Therapeutics and Renovaro. Learn More about companies similar to Neoleukin Therapeutics.

How do I contact Neoleukin Therapeutics' investor relations team?

Neoleukin Therapeutics' physical mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The company's listed phone number is (866) 245-0312 and its investor relations email address is [email protected]. The official website for Neoleukin Therapeutics is www.neoleukin.com. Learn More about contacing Neoleukin Therapeutics investor relations.